Osteosarcomas remain an enigmatic group of malignancies that share in common the presence of transformed cells producing osteoid matrix, even if these cells comprise a minority of the tumor volume. The differentiation state of osteosarcomas has therefore become a topic of interest and challenge to those who study this disease. In order to test how the cell of origin contributes to the final state of differentiation in the transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the cell cycle checkpoint tumor-suppressor genes Trp53 and Rb1 using Prx1-Cre, Collagen-1α1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme, preosteoblasts and mature osteoblasts, respectively. The Prx1 and Col1α1 lineages developed tumors with nearly complete penetrance, as anticipated. Osteosarcomas also developed in 44% of Oc-Cre;Rb1 fl/fl ;Trp53 fl/fl mice. We confirmed using 5-ethynyl-2′-deoxyuridine click chemistry that the Oc-Cre lineage includes very few actively cycling cells. By assessing radiographic mineralization and histological osteoid production, the differentiation state of tumors did not correlate with the differentiation state of the lineage of origin. Some of the osteocalcin-lineage-derived osteosarcomas were among the least osteoblastic. Osteocalcin immunohistochemistry in tumors correlated well with the expression of DNA methyl transferases, suggesting that silencing of these epigenetic regulators may influence the final differentiation state of an osteosarcoma. Transformation of differentiated, minimally proliferative osteoblasts is possible but may require such an epigenetic reprogramming that the tumors no longer resemble their differentiated origins.
INTRODUCTION
The recognition of stem-like characteristics among cancerinitiating cells has reinvigorated the debated relationship between differentiation and oncogenesis. 1, 2 There is no doubt that many malignant cells exhibit differentiation that is blunted relative to their host tissue to some degree, 3 but any single tumor may also include cells at varied states of differentiation. 4 Much of the related experimental work in solid tumors has been performed using carcinogenesis in epithelial tissues as a model, in which differentiation states of potential originating cells will map to specific locations in a crypt or gland. 5 Osteosarcomagenesis provides another useful model, in that the gamut of osteoblast differentiation is well delineated by marker gene expression profiles, 6, 7 and osteosarcomas bear incomplete osteoblast differentiation characteristics. [8] [9] [10] Osteosarcoma is the most common primary malignancy of bone and is a leading cause of cancer death among adolescents and young adults. [11] [12] [13] The diagnostic entity of osteosarcoma includes neoplasms with a range of morphologies and cellular characteristics. 14 Histopathologically, the single diagnostic feature that all osteosarcomas share in common is the presence of malignant cells producing osteoid matrix. 13 It is the presence of such cells-not their predominance-that renders the diagnosis of osteosarcoma. The malignant-appearing cells producing osteoid matrix may comprise a large or small portion of the overall tissue volume in a given tumor. In addition, osteosarcomas may be composed of osteoblastic, chondroblastic, fibroblastic and/or telangiectatic (vascular spaces) tissue types. [15] [16] [17] Osteosarcomas have been evaluated for their expression of osteoblast differentiation marker genes. 18 These marker gene profiles locate most osteosarcomas on the range of osteoblast differentiation at a point near preosteoblasts, expressing some lineage-committed markers, but often lacking expression of the markers of terminal differentiation and cell cycle exit, such as osteocalcin. [18] [19] [20] Given this observation, as well as the widely variable differentiation state of the bulk of neoplastic cells in osteosarcomas, many have debated whether the cell of origin or the transforming events themselves contribute more to the final differentiation state of the tumor. 14 The loss of P53 or RB1, each associated with osteosarcoma, has been shown to impact osteoblast differentiation powerfully in ways that are likely independent from their tumor-suppressor roles, the former actually moving undifferentiated mesenchyme toward the osteoblast lineage. [19] [20] [21] [22] [23] A number of investigators have induced osteosarcomas in mice by disrupting cell cycle checkpoint tumor-suppressor genes at early stages of osteoblast differentiation. [24] [25] [26] [27] Prior work has indicated that some measure of reversed differentiation (or dedifferentiation) is possible during osteosarcomagenesis, in that the tumor cells often mimic less differentiated osteoblasts than the cells of origin. 28 What is not clear is how far along osteoblast differentiation this principle can be extended. One prior study drove SV40 T antigen by elements of the osteocalcin promoter in a transgene. 29 This suggested that osteosarcomagenesis initiated late in differentiation is possible but did not permit precise localization of the initiation state along the course of differentiation as osteocalcin promoter elements can lead to variable expression along that course. This recommends initiation from a better known cell of origin using well-characterized drivers. Further, we do not yet know how the differentiation state of the cell of origin impacts the final differentiation state of the tumor cells, for which head-to-head comparisons are needed.
RESULTS AND DISCUSSION
For a head-to-head comparison, we compared the relative tumorigenicity of conditional disruption of the cell cycle checkpoint tumor-suppressor genes Trp53 and Rb1 using osteoblast-related promoters for Cre-recombinase in the mouse at different stages along the course of osteoblast differentiation (Figure 1a ). To transform relatively undifferentiated mesenchyme, we used Prx1-Cre. 30 For the preosteoblast stage, we used Col1α1-Cre. 31 Although another Cre-recombinase driven by a portion of the Col1α1 promoter was previously used to induce osteosarcomas by conditional Trp53 disruption, 22 that particular transgene has been noted to display 'leaky' expression in earlier stages of mesenchymal differentiation. 32 Therefore the prior osteosarcoma model may have derived either from earlier, leaky expression or from preosteoblast expression of Cre leading to Cre-mediated Trp53 disruption. The particular Col1α1-Cre selected for our experiments has been shown to be more specific to the preosteoblast and osteoblast stages of differentiation. 31, 33 To disrupt the tumor suppressors in terminally differentiated osteoblasts, we used osteocalcin-Cre (Oc-Cre). 34 Although transgenes with portions of the osteocalcin promoter have led to expression broadly crossing the range of osteoblast differentiation, this particular transgene has been shown to have expression limited to committed, mature, terminally differentiated osteoblasts and osteocytes. 34 For this study, mice with loxP-flanked, conditional alleles of Trp53 and Rb1 were crossed to produce offspring with homozygosity for each allele. Similar to prior studies, the strong majority of Prx1-Cre;Rb1 fl/fl ;Trp53 fl/fl mice developed tumors. 30 Distinct from the prior report, nearly all mice in our cohort developed sarcomas involving the skeleton directly, detected by plain radiography and gross dissection; a few had soft-tissue sarcomas as well or instead ( Supplementary Table S1 ). We limited our additional experiments to the tumors involving the skeleton.
Col1α1-Cre;Rb1 fl/fl ;Trp53 fl/fl mice also developed osteosarcomas efficiently. This was not surprising, as prior Cre-recombinase transgenes driven by the Col1a1 promoter and effecting Trp53 loss have led to osteosarcomagenesis. 22 Nonetheless, the more specific and more differentiated state of the early osteoblasts expressing this particular Col1α1-Cre suggested that this later stage of differentiation is also capable of transformation.
Much more surprising was osteosarcomagenesis arising from Oc-Cre;Rb1 fl/fl ;Trp53 fl/fl mice. The expression of osteocalcin itself is considered to begin simultaneously with cell cycle exit. We therefore had not anticipated that disrupted cell cycle checkpoint regulation would have any impact in osteocalcin-expressing osteoblasts. However, regardless of the initial differentiation state of the cell, osteosarcomagenesis was inducible via Trp53 and Rb1 homozygous ablation, as evidenced by skeletally destructive neoplasms that histopathologically displayed the presence of malignant cells producing osteoid matrix arising from all three lineages ( Figure 1b similar latency to osteosarcomagenesis in each lineage (Figure 1d ). However, many Oc-Cre;Rb1 fl/fl ;Trp53 fl/fl mice died or became morbid without forming tumors (noted as censored). The lower incidence but similar latency to osteosarcomagenesis in the Oc-Cre lineage suggests that these cells may have a higher hurdle to pass with secondary perturbations, but that the opportunity to accrue such secondary hits is limited. As this transgene is expressed sometime near cell cycle exit, it may be that cells must have already accrued any necessary additional hits prior to the controlled disruption of Trp53 and Rb1.
In order to confirm that expression of Oc-Cre follows cessation of proliferation, we crossed mice bearing each Cre-recombinase transgene to a tandem dimer Tomato (tdTomato) conditional reporter line. We then harvested embryos 2 days following reporter initiation of expression during embryogenesis, embryonic day 11.5 for the Prx1-Cre lineage, embryonic day 17.5 for the Col1α1-Cre lineage and postnatal day 1 for the Oc-Cre lineage. Four hours prior to harvest, 5-ethynyl-2′-deoxyuridine was administered by intraperitoneal injection to label actively cycling cells (Figure 2a ). This experiment identified that o 2% of the Oc-Cre lineage were actively synthesizing DNA, confirming the very late differentiation state and predominantly non-proliferating status of these cells (Figure 2b) . These results were consistent with previous studies that identified osteocalcin and this particular Cre-recombinase transgene as a marker of terminal differentiation and cell cycle exit. [18] [19] [20] Importantly, these results show that osteosarcomagenesis followed loss of function in tumorsuppressor genes Trp53 and Rb1 even after osteoblasts are fully mature and minimally proliferative.
The possibility that all Oc-Cre-induced tumors arose from this tiny sub-population of proliferative osteoblasts is challenged by the relatively high incidence of tumors from this lineage (44%). Although lower than the incidence from the Prx1-Cre and Col1α1-Cre lineages, some mice from which had more than one tumor, the Oc-Cre-induced incidence was not even close to proportional to the actively proliferative number of cells in the less differentiated lineages. This suggests that slowing of proliferation or even exit from cell cycle might not protect against transformation.
In order to quantify the osteoblastic differentiation state of the skeletal tumors derived from tumor suppressor silencing in the Prx1-Cre, Col1α1-Cre and Oc-Cre lineages, we assessed tumors with radiographs obtained at the time of euthanasia for morbidity. The number of Prx1-Cre;Rb1 fl/fl ;Trp53 fl/fl , Col1α1-Cre;Rb1 fl/fl ;Trp53 fl/fl and Oc-Cre;Rb1 fl/fl ;Trp53 fl/fl tumors assessed via radiographs was 48, 48 and 18, respectively. Each skeleton-associated tumor was classified according to mineralization density relative to the femoral diaphysis by an evaluator unaware of the host animal's genotype. Tumors were classified on a scale of 1-4, with class 1 having no radiographically apparent mineralization, class 2 having mineralization present but at a density less than the femoral diaphysis, class 3 having mineralization density similar to the femoral diaphysis and class 4 having more dense mineralization than the femoral diaphysis ( Figure 3a ). Transformation in each of the three lineages led to a wide range of mineralization states in the resultant tumors (Figure 3b ). We concluded that the differentiation state of the cell of origin did not correlate with mineralization in the resultant tumor. Surprisingly, some tumors derived from the Oc-Cre lineage had little-to-no mineralization, despite the robust mineralizing capacity of the cells from which they derived.
In order to quantify the osteoblastic differentiation state of tumors by another means, tumors were harvested, fixed, embedded in paraffin and sectioned. Mid-cross-sections were obtained and stained with hematoxylin and eosin for standard histopathology. An observer blinded to the genotype of the host mouse measured the cross-sectional area represented by each classed production of osteoid matrix (Figure 3d ). Importantly, the matrix production in tumors did not correlate with the initial differentiation state of the cell of origin. In fact, there were more minimal-matrix-producing tumors arising from the Oc-Cre lineage than from the Prx1-Cre lineage.
The wide variation in the mineralization and matrix production in osteosarcomas arising from the Oc-Cre lineage suggested that some degree of de-differentiation had taken place during or after transformation. To investigate this further, we performed immunofluorescence against Cre-recombinase in some low-and high-matrix producing Oc-Cre-induced tumors. The low-matrix Oc-Cre-induced tumors no longer demonstrated Oc-Cre expression from its differentiation-associated promoter, but their high-matrix counterparts retained Cre expression ( Figure 4a ).
This confirmed loss of expression from a differentiationassociated transgene suggested that some genetic or epigenetic re-set during transformation had altered the differentiation state of the cell. Because DNA methylation has an established role in osteoblast differentiation, we next tested the expression of three DNA methyl transferases (Dnmt1, Dnmt3a, Dnmt3b) as well as osteocalcin in the tumors, each by immunohistochemistry ( Figure 4b ). Tumors were ranked by two blinded investigators for each stain. Osteocalcin ranking did not correlate whatsoever with the lineage of origin (Figure 4c ) but correlated loosely with matrix production ranking, as expected (Figure 4d ). Osteocalcin ranking also correlated strongly with the mean Dnmt immunohistochemical ranking for each tumor. This suggests that one potential route toward epigenetic re-setting of a tumor's differentiation state may come through silencing or loss of DNA methyl transferases.
We report that conditional disruption of Trp53 and Rb1 using osteoblast-related promotors for Cre-recombinase expression in the mouse proved to be sufficient for osteosarcomagenesis in not only mesenchymal pluripotent progenitor cells and preosteoblasts but also in mature osteoblasts that had largely stopped proliferating. Furthermore, the final differentiation state of tumors did not correlate with the differentiation state of the lineage from which they originated but did correlate with expression levels of DNA methyl transferases, suggesting that epigenetic re-setting had taken place during or after transformation in the dedifferentiated tumors.
It is important to note that while the findings of this study suggest that cell cycle checkpoint loss can lead to transformation even in almost non-proliferative cells, the same may or may not be mechanistically happening in the generation of clinically relevant human osteosarcomas. In mice, we can only test sufficiency for transforming genetic events, not necessity. Understanding the cells of origin that enable transformation may help us understand some of the intrinsic vulnerabilities of the cancer cells that our therapies may target and exploit. In converse, they may also elucidate inherent strengths of the cells that will be unlikely to be overcome with biological therapies. The generation of an indiscernibly different range of osteosarcomas at only a slightly lower incidence when beginning from a terminally differentiated osteoblast population versus a proliferative stem-like progenitor population argues that osteosarcomagenesis can include a significant re-set of differentiation. That such is possible suggests that recent attempts at differentiation therapy 35, 36 would have to overcome powerful de-differentiation programs set in motion during tumor initiation.
